--------------------------------------------------------------------------------

Exhibit 10.1

THIRD AMENDMENT AGREEMENT

THIRD AMENDMENT AGREEMENT, dated as of January 16, 2019 (this "Agreement"), by
and among Seelos Therapeutics, Inc., a Delaware corporation, ("Seelos"), Apricus
Biosciences, Inc., a Nevada corporation ("Apricus"), and the investor listed on
the signature pages attached hereto (the "Investor"). All terms used and not
defined herein are used as defined in the Securities Purchase Agreement and the
Warrants (each as defined below), as applicable.

WHEREAS, Apricus and Seelos entered into that certain Securities Purchase
Agreement, dated as of October 16, 2018 (as amended pursuant to that certain
Amendment Agreement, dated November 16, 2018, by and among the parties thereto
(the "First Amendment"), and that certain Second Amendment Agreement, dated
January 4, 2019, by and among the parties thereto (the “Second Amendment”), the
"Securities Purchase Agreement"), with the Investor, a Buyer, and the other
Buyers listed on the signature pages attached thereto;

WHEREAS, pursuant to the Securities Purchase Agreement: (i) Seelos agreed to
issue to the Investor (x) the number of Initial Common Shares set forth opposite
the Investor's name in column (3) of the Schedule of Buyers attached to the
Securities Purchase Agreement and (y) up to the number of Additional Common
Shares set forth opposite the Investor's name in column (4) of the Schedule of
Buyers attached to the Securities Purchase Agreement and (ii) Apricus agreed to
issue to the Investor (x) Series A Warrants to acquire Apricus Common Stock in
the form attached as Exhibit B-1 to the Securities Purchase Agreement (the
"Series A Warrants") and (y) Series B Warrants to acquire Apricus Common Stock
in the form attached as Exhibit B-2 to the Securities Purchase Agreement (the
"Series B Warrants" and, together with the Series A Warrants, the "Warrants"),
in each case, subject to the terms and conditions set forth in the Securities
Purchase Agreement;

WHEREAS, Section 9 of the Second Amendment provides that any amendments or
modifications thereto must be executed in writing by all parties thereto,
provided, for the avoidance of doubt, that any amendment to any of the
Transaction Documents shall be effected in accordance with the terms of the
applicable Transaction Document;

WHEREAS, Section 10(e) of the Securities Purchase Agreement provides that
written consent of the Required Holders (as defined therein) shall be required
for any change or amendment to the Securities Purchase Agreement, including,
without limitation, any exhibit attached thereto; and

WHEREAS, in compliance with Section 9 of the Second Amendment and Section 10(e)
of the Securities Purchase Agreement, this Agreement shall only be effective and
binding on all Buyers upon the execution and delivery of this Agreement and
agreements in form and substance identical to this Agreement (other than with
respect to the identity of the Investor and proportional changes reflecting the
different holdings of the Buyers) (the "Other Agreements" and together with this
Agreement, the "Agreements") entered into by and among Seelos, Apricus and such
other Buyers who, collectively with the Investor, represent the Required Holders
(as defined in the Securities Purchase Agreement) (such time, the "Effective
Time").
 
1

--------------------------------------------------------------------------------

NOW, THEREFORE, in consideration of the premises and the mutual agreements,
provisions and covenants contained herein, the receipt and sufficiency of which
are hereby acknowledged, the parties hereby agree as follows:

1.         Amendments. Section 1 of the Second Amendment is hereby amended and
restated as follows:

1.          Amendments. The Series A Warrants shall be in the form of Exhibit
B-1 attached to the Securities Purchase Agreement, except as follows:

(A)       The Form of the Series A Warrant attached as Exhibit B-1 to the
Securities Purchase Agreement is hereby amended by amending Section 1(g) thereof
to delete the following language:

"In the event that upon any exercise of this Warrant, the Company does not have
sufficient authorized shares to deliver in satisfaction of such exercise, then
unless the Holder elects to void such attempted exercise, the Holder may require
the Company to pay to the Holder within three (3) Trading Days of the applicable
exercise, cash in an amount equal to the product of (i) the number of Warrant
Shares that the Company is unable to deliver pursuant to this Section 1(g) and
(ii) the highest Weighted Average Price during the period beginning on the date
of such attempted exercise and the date that the Company makes the applicable
cash payment."

(B)       The Form of the Series A Warrant attached as Exhibit B-1 to the
Securities Purchase Agreement is hereby amended by amending Section 4(c) thereof
to add the language in italics, as follows:

"Notwithstanding the foregoing, in the event of a Fundamental Transaction, at
the request of the Holder delivered before the ninetieth (90th) day after the
occurrence or consummation of such Fundamental Transaction, the Company (or the
Successor Entity) shall purchase this Warrant from the Holder by paying to the
Holder, within five (5) Business Days after such request (or, if later, on the
effective date of the Fundamental Transaction), cash in an amount equal to the
Black Scholes Value of the remaining unexercised portion of this Warrant on the
date of such Fundamental Transaction; provided, however, if the Fundamental
Transaction is not within the Company's control, including not approved by the
Company's Board of Directors, the Holder shall only be entitled to receive from
the Company or any Successor Entity, as of the date of consummation of such
Fundamental Transaction, the same type or form of consideration (and in the same
proportion), at the Black Scholes Value of the unexercised portion of this
Warrant, that is being offered and paid to the holders of Common Stock in
connection with such Fundamental Transaction, whether that consideration be in
the form of cash, stock or any combination thereof, or whether the holders of
Common Stock are given the choice to receive from among alternative forms of
consideration in connection with such Fundamental Transaction."
 
2

--------------------------------------------------------------------------------

(C)       The definition of "Black Scholes Consideration Value" set forth in
Section 17(g) of the Form of the Series A Warrant attached as Exhibit B-1 to the
Securities Purchase Agreement is hereby amended and restated as follows (changes
shown):

"[INSERT IN SERIES A WARRANT: "Black Scholes Consideration Value" means the
value of the applicable Option, Convertible Security or Adjustment Right (as the
case may be) calculated using the Black Scholes Option Pricing Model obtained
from the "OV" function on Bloomberg determined as of the date of issuance
thereof and reflecting (i) a risk-free interest rate corresponding to the U.S.
Treasury rate for a period equal to the remaining term of such Option,
Convertible Security or Adjustment Right (as the case may be) as of the date of
issuance of such Option, Convertible Security or Adjustment Right (as the case
may be), (ii) an expected volatility equal to the greater of 100% and the 100
day volatility obtained from the HVT function on Bloomberg as of the Trading Day
immediately following the public announcement of the issuance of such Option,
Convertible Security or Adjustment Right (as the case may be), or, if the
issuance of such Option, Convertible Security or Adjustment Right (as the case
may be) is not publicly announced, the date of issuance of such Option,
Convertible Security or Adjustment Right (as the case may be), (iii) the
underlying price per share used in such calculation shall be the average of the
Weighted Average Prices highest Weighted Average Price of the Common Stock
during the period beginning on the Trading Day prior to the execution of
definitive documentation relating to the issuance of such Option or Convertible
Security (as the case may be) and ending on (A) the Trading Day immediately
following the public announcement of the execution of definitive documents with
respect to the issuance of such Option or Convertible Security (as the case may
be), or, (B) if the execution of definitive documents with respect to the
issuance of such Option or Convertible Security (as the case may be) is not
publicly announced, the date of such issuance, (iv) a zero cost of borrow and
(v) a 365 day annualization factor.] [INSERT IN SERIES B WARRANT: Intentionally
omitted.]"
 
3

--------------------------------------------------------------------------------

(D)        The definition of "Black Scholes Value" set forth in Section 17(h) of
the Form of the Series A Warrant attached as Exhibit B-1 to the Securities
Purchase Agreement is hereby amended and restated as follows (changes shown):

"[INSERT IN SERIES A WARRANT: "Black Scholes Value" means the value of this
Warrant calculated using the Black-Scholes Option Pricing Model obtained from
the "OV" function on Bloomberg determined as of the day immediately following
the public announcement of the applicable Fundamental Transaction, or, if the
Fundamental Transaction is not publicly announced, the date the Fundamental
Transaction is consummated, for pricing purposes and reflecting (i) a risk-free
interest rate corresponding to the U.S. Treasury rate for a period equal to the
remaining term of this Warrant as of such date of request, (ii) an expected
volatility equal to the greater of 100% and the 100 day volatility obtained from
the HVT function on Bloomberg as of the Trading Day immediately following the
public announcement of the applicable Fundamental Transaction, or, if the
Fundamental Transaction is not publicly announced, the date the Fundamental
Transaction is consummated, (iii) the underlying price per share used in such
calculation shall be the greater of (x) the average of the Weighted Average
Prices highest Weighted Average Price of the Common Stock during the period
beginning on the Trading Day prior to the execution of definitive documentation
relating to the applicable Fundamental Transaction and ending on (A) the Trading
Day immediately following the public announcement of such Fundamental
Transaction, if the applicable Fundamental Transaction is publicly announced or
(B) the Trading Day immediately following the consummation of the applicable
Fundamental Transaction if the applicable Fundamental Transaction is not
publicly announced and (y) the sum of the price per share being offered in cash,
if any, plus the value of any non-cash consideration, if any, being offered in
the Fundamental Transaction, (iv) a zero cost of borrow and (v) a 365 day
annualization factor.] [INSERT IN SERIES B WARRANT: Intentionally omitted."
 
4

--------------------------------------------------------------------------------

(E)       Section 9 of the Securities Purchase Agreement is hereby amended by
deleting the reference to "December 31, 2018" and replacing it with "January 31,
2019".

(F)        Section 5(h) of the Securities Purchase Agreement is hereby amended
by deleting the reference to "$100,000" and replacing it with "$130,000".

2.          Effectiveness. This Agreement shall become effective as of the
Effective Time.

3.          Ratifications. Except as otherwise expressly provided herein, each
Transaction Document, is, and shall continue to be, in full force and effect and
is hereby ratified and confirmed in all respects, except that (i) all references
in the Securities Purchase Agreement to "this Agreement", "hereto", "hereof",
"hereunder" or words of like import referring to the Securities Purchase
agreement shall mean the Securities Purchase Agreement as amended by the First
Amendment, the Second Amendment and this Agreement and (ii) on and after the
Closing Date all references in the Warrants to "this Warrant", "hereto",
"hereof", "hereunder" or words of like import referring to the Warrants shall
mean the Warrants as amended by the First Amendment, the Second Amendment and
this Agreement.

4.          Representations and Warranties. The Investor represents and warrants
to each of Apricus and Seelos, and each of Apricus and Seelos, severally and not
jointly, represents and warrants to the Investor as of the date hereof and as of
the Effective Time that: Such Person is an entity duly organized and validly
existing under the laws of the jurisdiction of its formation, has the requisite
power and authority to execute and deliver this Agreement and to carry out and
perform all of its obligations under the terms of this Agreement; this Agreement
has been duly executed and delivered on behalf of such Person, and this
Agreement constitutes the valid and legally binding obligation of such Person
enforceable against such Person in accordance with its terms, except as such
enforceability may be limited by general principles of equity or to applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation and other
similar laws relating to, or affecting generally, the enforcement of applicable
creditors' rights and remedies; the execution, delivery and performance by such
Person of this Agreement and the consummation by such Person of the transactions
contemplated hereby will not (i) result in a violation of the organizational
documents of such Person, (ii) conflict with, or constitute a default (or an
event which with notice or lapse of time or both would become a default) under,
or give to others any rights of termination, amendment, acceleration or
cancellation of, any agreement, indenture or instrument to which such Person is
a party, or (iii) result in a violation of any law, rule, regulation, order,
judgment or decree (including federal and state securities laws) applicable to
such Person, except in the case of clause (ii) and (iii) above, for such
conflicts, defaults, rights or violations which would not, individually or in
the aggregate, reasonably be expected to have a material adverse effect on the
ability of such Person to perform its obligations hereunder.
 
5

--------------------------------------------------------------------------------

5.          Disclosure. On or before 8:30 a.m., New York City time, on January
17, 2019, Apricus shall file a Current Report on Form 8-K describing the terms
of the transactions contemplated hereby in the form required by the 1934 Act and
attaching the form of this Agreement as an exhibit to such filing (the "8-K
Filing"). From and after the filing of the 8-K Filing with the SEC, each of
Apricus and Seelos hereby acknowledges and agrees that the Investor shall not be
in possession of any material, nonpublic information received from Apricus or
Seelos, any of their respective Subsidiaries or any of their respective
officers, directors, affiliates, employees or agents, that is not disclosed in
the 8-K Filing. Each of Apricus and Seelos understands and confirms that the
Investor will rely on the foregoing in effecting transactions in securities of
Apricus and Seelos.

6.      Governing Law; Jurisdiction; Jury Trial. All questions concerning the
construction, validity, enforcement and interpretation of this Agreement shall
be governed by the internal laws of the State of New York, without giving effect
to any choice of law or conflict of law provision or rule (whether of the State
of New York or any other jurisdictions) that would cause the application of the
laws of any jurisdictions other than the State of New York. Each party hereby
irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in The City of New York, Borough of Manhattan, for the
adjudication of any dispute hereunder or in connection herewith or with any
transaction contemplated hereby or discussed herein, and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of any such court, that
such suit, action or proceeding is brought in an inconvenient forum or that the
venue of such suit, action or proceeding is improper. Each party hereby
irrevocably waives personal service of process and consents to process being
served in any such suit, action or proceeding by mailing a copy thereof to such
party at the address for such notices to it under the Securities Purchase
Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof to the fullest extent enforceable under
applicable law. Nothing contained herein shall be deemed to limit in any way any
right to serve process in any manner permitted by law. EACH PARTY HEREBY
IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY
TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR
ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

7.         Counterparts; Headings. This Agreement may be executed in two or more
counterparts, each of which will be deemed an original but all of which together
will constitute one and the same instrument. The headings of this Agreement are
for convenience of reference and shall not form part of, or affect the
interpretation of, this Agreement.

8.        Severability. If any provision of this Agreement is prohibited by law
or otherwise determined to be invalid or unenforceable by a court of competent
jurisdiction, the provision that would otherwise be prohibited, invalid or
unenforceable shall be deemed amended to apply to the broadest extent that it
would be valid and enforceable, and the invalidity or unenforceability of such
provision shall not affect the validity of the remaining provisions of this
Agreement so long as this Agreement as so modified continues to express, without
material change, the original intentions of the parties as to the subject matter
hereof and the prohibited nature, invalidity or unenforceability of the
provision(s) in question does not substantially impair the respective
expectations or reciprocal obligations of the parties or the practical
realization of the benefits that would otherwise be conferred upon the parties.
The parties will endeavor in good faith negotiations to replace the prohibited,
invalid or unenforceable provision(s) with a valid provision(s), the effect of
which comes as close as possible to that of the prohibited, invalid or
unenforceable provision(s).
 
6

--------------------------------------------------------------------------------

9.          Amendments. Any amendments or modifications hereto must be executed
in writing by all parties hereto, provided, for the avoidance of doubt, that any
amendment to any of the Transaction Documents shall be effected in accordance
with the terms of the applicable Transaction Document.

[Signature Page Follows]
 
7

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date
first above written.

 
APRICUS BIOSCIENCES, INC.
       
By:
 
   
Name: Richard W. Pascoe
   
Title: Chief Executive Officer

[Signature Page to 3rd Amendment Agreement]
 

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date
first above written.

 
SEELOS THERAPEUTICS, INC.
       
By:
 
   
Name: Raj Mehra, Ph.D.
   
Title: Chief Executive Officer

[Signature Page to 3rd Amendment Agreement]
 

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date
first above written.

INVESTOR:

Name of Investor: ________________________________________________________

Signature of Authorized Signatory of Investor: _________________________________

Name of Authorized Signatory: _______________________________________________

Title of Authorized Signatory: ________________________________________________

[Signature Page to 3rd Amendment Agreement]

--------------------------------------------------------------------------------